Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.7.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Apr. 30, 2017
Apr. 30, 2016
Apr. 30, 2017
Apr. 30, 2016
Revenues:        
Clinical laboratory services $ 19,584 $ 18,162 $ 56,979 $ 52,775
Product revenues 7,312 8,001 21,721 22,266
Royalty and license fee income 193 270 933 1,129
Total revenues 27,089 26,433 79,633 76,170
Operating costs, expenses and legal settlements, net:        
Cost of clinical laboratory services 11,334 11,142 33,282 32,009
Cost of product revenues 3,582 3,846 10,411 10,663
Research and development 766 882 2,071 2,610
Selling, general and administrative 10,502 10,869 33,141 32,374
Provision for uncollectible accounts receivable 620 576 1,968 1,739
Legal fee expense 512 1,632 1,254 5,644
Legal settlements, net       (18,450)
Total operating costs, expenses and legal settlements, net 27,316 28,947 82,127 66,589
Operating income (loss) (227) (2,514) (2,494) 9,581
Other income (expense):        
Interest 115 (40) 240 (122)
Other (74) 22 69 87
Foreign exchange gain (loss) 147 419 (308) (99)
Income (loss) before income taxes (39) (2,113) (2,493) 9,447
Provision for income taxes (32) (2) (105) (296)
Net income (loss) $ (71) $ (2,115) $ (2,598) $ 9,151
Net income (loss) per common share:        
Basic (in Dollars per share) $ 0.00 $ (0.05) $ (0.06) $ 0.20
Diluted (in Dollars per share) $ 0.00 $ (0.05) $ (0.06) $ 0.20
Weighted average common shares outstanding:        
Basic (in Shares) 46,367 46,201 46,310 46,115
Diluted (in Shares) 46,367 46,201 46,310 46,450